TiGenix : to present at BIO CEO & Investor Conference & key meetings in H1 2014

LEUVEN, Belgium, Jan. 21, 2014 (GLOBE NEWSWIRE) -- TiGenix (NYSE Euronext: TIG), a leader in the field of cell therapy, announced today that Eduardo Bravo, CEO, will be presenting at the 16th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the BIO CEO & Investor Conference will take place February 10-11 at the Waldorf Astoria in New York City.

Additionally, during the first half of 2014 the company will present at a number of key events in Europe and the U.S. geared at investor and industry audiences.

February 10-11
BIO CEO & Investor Conference, The Waldorf Astoria, New York, NY, U.S.
Presenter: Eduardo Bravo, CEO

February 18
9th Annual Stem Cell Summit, The Convene, New York, NY, U.S.
Presenter: Eduardo Bravo, CEO

March 4-5
European Life Science CEO Forum, Airport Hilton, Zurich, Switzerland
Presenter: Eduardo Bravo, CEO

March 10-12
BIO-Europe Spring, Conference Center OVAL Lingotto, Turin, Italy
Attendees: Eduardo Bravo, CEO - Claudia Jiménez, Senior Director Corporate Development

March 20
KBC Healthcare Conference, Brussels, Belgium
Attendees: Eduardo Bravo, CEO - Claudia D'Augusta, CFO

March 22
RegenMed Investor Day, New York, NY, U.S.
Presenter: Eduardo Bravo, CEO

March 27
BioCapital, The Grand, Amsterdam, the Netherlands
Presenter: Claudia D'Augusta

March 31 - April 1
7th Annual Kempen & Co Healthcare Conference, Amsterdam, the Netherlands
Attendees: Eduardo Bravo, CEO - Claudia D'Augusta, CFO

April 7-8
9th edition European Smallcap Event, Paris, France
Attendees: Eduardo Bravo, CEO - Claudia D'Augusta, CFO

May 20-22
9th Annual World Stem Cell & Regenerative Medicine Congress, London, UK
Presenter: Eduardo Bravo, CEO

May 21-22
BioEquity Europe 2014, Amsterdam, the Netherlands
Presenter: Claudia D'Augusta, CFO

June 23-26
Bio International Convention, San Diego, U.S.
Attendees: Eduardo Bravo, CEO - Claudia Jiménez, Senior Director Corporate Development

For more information:
Eduardo Bravo
Chief Executive Officer

Claudia D'Augusta
Chief Financial Officer

Hans Herklots
Director Investor & Media Relations
+32 16 39 60 97

About TiGenix

TiGenix NV (NYSE Euronext Brussels: TIG) is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect®, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit www.tigenix.com.

Forward-looking information

This document may contain forward-looking statements and estimates with respect to the anticipated future performance of TiGenix and the market in which it operates. Certain of these statements, forecasts and estimates can be recognised by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond TiGenix' control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in TiGenix' expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by Belgian law.